Experts discuss best practices for improving patient adherence to hemophilia A therapies, including addressing adherence issues and patient engagement.
While clinical trials offer controlled data, real-world studies like HEM-POWR bridge gaps, confirming damoctocog alfa pegol’s effectiveness and tolerance, establishing it as a valuable hemophilia A treatment option.